Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) today announced presentations on plecanatide and SP-333, its proprietary guanylate cyclase-C (GC-C) agonists in development for gastrointestinal (GI) disorders, will take place at two scientific meetings this month.
Plecanatide, Synergy’s lead GC-C agonist for chronic idiopathic constipation and irritable bowel syndrome with constipation, will be featured in two oral presentations at the United European Gastroenterology (UEG) Week being held October 12-16 in Berlin, Germany.
Updated pre-clinical data on SP-333, the company’s next-generation GC-C agonist being studied for opioid-induced constipation and inflammatory bowel disease, will be featured in two poster presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting being held October 11-16 in San Diego, California.
Plecanatide Oral Presentations - UEG 2013
Abstract: Acceleration of Time to First Bowel Movement in Chronic Idiopathic Constipation (CIC) Patients Receiving Plecanatide in a Large, Multicenter, Dose-Ranging StudyDate & Time: Tuesday, October 15
, 8:42am – 8:54amAbstract Number: OP155Presenting Author: Ronald P. Fogel, M.D. (Digestive Health Centers of Michigan)
Abstract: Plecanatide Produces a Diarrhea Plateau Effect in Chronic Idiopathic Constipation (CIC) PatientsDate & Time: Tuesday, October 15
, 10:18am – 10:30amAbstract Number: OP163Presenting Author: Ronald P. Fogel, M.D. (Digestive Health Centers of Michigan)
SP-333 Poster Presentations – ACG 2013
Abstract: Oral Treatment with SP-333, an Agonist of Guanylate Cyclase-C, Dramatically Ameliorates Morphine-Induced Bowel Dysfunction in RatsDate & Time: Tuesday, October 15
, 10:30am – 4:00pmPoster Number: P1091Presenting Author: Kunwar Shailubhai, Ph.D., M.B.A.Note:
“ACG’s 2013 Presidential Poster Award.”
Posters receiving this award accumulated scores in the top five percent of the posters submitted for the ACG Annual Meeting in San Diego, CA.
Abstract: SP-333, a Guanylate Cyclase-C Agonist, Inhibits NF-kB Signaling and Modulates Related Genes and miRNAs Implicated in GI Inflammation and CarcinogenesisDate & Time: Monday, October 14
, 10:30am – 4:00pmPoster Number: P1049Presenting Author: Kunwar Shailubhai, Ph.D., M.B.A.
About Synergy Pharmaceuticals Inc.
Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of new drugs to treat patients with gastrointestinal (GI) diseases and disorders. Synergy's lead proprietary drug candidate, plecanatide, is a synthetic analog of the human GI hormone, uroguanylin, and functions by activating the guanylate cyclase-C (GC-C) receptor on epithelial cells of the GI tract. In early 2013, Synergy announced positive results from a large multicenter trial of plecanatide in patients with chronic idiopathic constipation (CIC) and recently completed an end-of-phase 2 meeting with the U.S. Food and Drug Administration (FDA) covering the registration program for plecanatide to treat CIC. The company plans to initiate the phase 3 registration trial for plecanatide in CIC this quarter. Synergy is also developing plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C), recently announcing that it had reached the halfway mark for total enrollment in a plecanatide phase 2b clinical trial in patients with IBS-C. Synergy’s second GC-C agonist, SP-333, is in clinical development to treat opioid-induced constipation and inflammatory bowel disease. SP-333 has completed a phase I study in healthy volunteers and will enter phase 2 trials for OIC in the fourth quarter of 2013. More information is available at